untitled h1
appendix ii - cyp3a4 inducers

| Strong CYP3A4 Inducers:                         |                   |
|-------------------------------------------------|-------------------|
| Generic Name                                    | Common Trade Name |
| Carbamazepine                                   | Tegretol          |
| Phenobarbital                                   | Lummal            |
| Dilantin                                        |                   |
| Phenytom                                        |                   |
| Rifampin                                        | Rifadin           |
| St. John's wart                                 | N/A               |
| Systemic dexamethasone                          | Decadron          |
| Strong* and clinically relevant moderate CYP3A4 |                   |
| Inhibitors:                                     |                   |
| Generic Name                                    | Common Trade Name |
| Aprepitant                                      | Emend             |
| Clarithromycin*                                 | Biaxm             |
| Erythromycin                                    | Eryc, EryPed      |
| Diflucan                                        |                   |
| Fluconazole                                     |                   |
| Grapefruit and its juice                        | N/A               |
| Itraconazole*                                   | Sporanox          |
| Nizoral                                         |                   |
| Ketoconazole*                                   |                   |
| Voriconazole                                    | VFend             |
| Posaconazole*                                   | Noxafil           |
untitled h1
references

1. Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin *Oncol.* 2014;32(27):3021-3032.  
2. Aplenc R, Meshinchi S, Sung L, et al. The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group. *Blood.* 2016;128(22).  
3. Gibson BE, Webb DK, Howman AJ, et al. Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. *Br J Haematol.*
2011;155(3):366-376.  
4. Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin *Oncol.* 2013;31(27):3360-3368.  
5. Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. *Blood.* 2012;120(8):1581-1588.  
6. Reulen RC, Winter DL, Frobisher C, et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA : the journal of the American Medical *Association.* 2010;304(2):172-179.  
7. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. Journal of the *National* Cancer *Institute.* 2001;93(8):618-629.  
8. Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J *Clin Oncol.* 2001;19(13):3163-3172.  
9. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J *Clin Oncol.* 2001;19(1):191-196.  
10. Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. *Lancet.*
2018;392(10147):593-606.  
11. Bernstein ID. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. *Leukemia.*
2000;14(3):474-475.  
12. van Der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. *Blood.* 2001;97(10):3197-3204.  
13. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer *Res.* 2001;7(6):1490-1496.  
14. Drexler HG. Classification of acute myeloid leukemias--a comparison of FAB and immunophenotyping. *Leukemia.* 1987;1(10):697-705.  
15. Estey EH, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamycin
("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. *Blood.* 2002;99(11):4222-4224.  
16. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. *Blood.* 2003;102(13):4277-4283.  
17. Amadori S, Suciu S, Willemze R, et al. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. *Haematologica.* 2004;89(8):950-956.  
18. Eom KS, Kim HJ, Min WS, et al. Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older. Eur *J Haematol.* 2007;79(5):398-404.  
19. Sievers EL. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33positive acute myeloid leukaemia in first relapse. Expert Opin *Biol Ther.* 2001;1(5):893901.  
20. Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin)
therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. *Cancer.* 2001;92(2):406-413.  
21. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. *Blood.* 2013;121(24):4854-4860.  
22. Rowe JM, Lowenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. *Blood.* 2013;121(24):4838-4841.  
23. Tarlock K, Alonzo TA, Gerbing RB, et al. Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clin Cancer *Res.* 2015.  
24. Pollard JA, Loken M, Gerbing RB, et al. CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. J Clin *Oncol.* 2016;34(7):747-755.  
25. Lamba JK, Pounds S, Cao X, et al. Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study. *Leukemia.* 2009;23(2):402-404.  
26. Mortland L, Alonzo TA, Walter RB, et al. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. Clin Cancer *Res.* 2013;19(6):1620-1627.  
27. Lamba JK, Chauhan L, Shin M, et al. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. J Clin *Oncol.* 2017;35(23):2674-2682.  
28. Mulrooney DA, Dover DC, Li S, et al. Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study. *Cancer.* 2008;112(9):2071-2079.  
29. Chellapandian D, Pole JD, Nathan PC, Sung L. Congestive heart failure among children with acute leukemia: a population-based matched cohort study. *Leuk Lymphoma.* 2018:1-10.  
30. Getz KD, Sung L, Ky B, et al. Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group. J Clin *Oncol.* 2019;37(1):12-21.  
31. Curran CF, Narang PK, Reynolds RD. Toxicity profile of dexrazoxane (Zinecard, ICRF187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity. Cancer Treat Rev. 1991;18(4):241-252.  
32. Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med *Chem.* 1998;5(1):1-28.  
33. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses.  
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 1990;4(13):3076-3086.  
34. Asselin BL, Devidas M, Chen L, et al. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. *J Clin Oncol.*
2016;34(8):854-862.  
35. Schwartz CL, Wexler LH, Krailo MD, et al. Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. Pediatr *Blood Cancer.* 2016;63(1):54-61.  
36. Kim H, Kang HJ, Park KD, et al. Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients. Cancer *Res Treat.* 2018.  
37. Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. *Blood.*
2001;97(1):89-94.  
38. Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. *Blood.* 2006;108(12):3654-3661.